Hi Dr. Freeman,
thank you for this article.
I have to admit that the information about RAS in this article is somehow puzzling for me, yet having been through the article, my understanding is that for a GT1 patient who relapsed after the SOF/LED treatment for 12 weeks, the alternatives are:
- either retreat with SOF/LED for 24 weeks (which seems to lead to almost 100% cure rate) // however this information is somehow contrasting the information about re-treatment options presented here
freepdfhosting.com/b3d39c5e48.pdf on page 14 - Ch. "Re-treatment Strategies after Failure of IFN-Free Treatment"
- either retreat with SOF/LED+ a 3rd DAA ( which one might this be? VEL?, VOX?, DAC? ) for 12 or 24 weeks.
Just an idea: would it be perhaps recommended and financially feasible, to treat GT1 patients right from the beginning with a combination of 3 generic DAAs? I would imagine that perhaps adding another ~100$ (that's just an imaginary cost ) to the generic treatment costs, the risk of relapse will be very very low, so a GT1 patient who might relapse (if treated with SOF/LED only) could save some time, money and stress by not having to retreat.
Cheers,
RHF